Senior analyst Pablo Zuanic of Zuanic & Associates outlines the transformative potential of new legislation in Germany's medical cannabis sector, forecasting market growth from a 28,000 patient base in 2023 to a value of €1.7 billion by 2025.
Zuanic emphasizes the nuanced reality behind Germany's cannabis "legalization," a gradual, phased approach to full legalization.
The initial phase allows for the possession, home cultivation and social clubs, though retail sales remain off-limits, posing potential risks and benefits.
A speculative second phase could introduce sales in select areas. Now, a question for investors arises: what drives this anticipated surge in Germany's medical marijuana market and how will the number of cash-paying medical marijuana users change?
Key Beneficiaries In the Surge
Zuanic's projections hinge on the assumption that 1% of Germany's roughly 85 million people will become medical marijuana cash payers, a stark increase from the current 0.03%.
He points to easier access and lower prices, facilitated by online clinics and pharmacies, alongside the new regulatory landscape, as key drivers of this growth.
"Medical cannabis was already federally legal ...